Lyell Immunopharma, Inc. (LYEL): Price and Financial Metrics

Lyell Immunopharma, Inc. (LYEL): $2.23

0.19 (+9.31%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add LYEL to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#141 of 365

in industry

LYEL Price/Volume Stats

Current price $2.23 52-week high $3.97
Prev. close $2.04 52-week low $1.32
Day low $2.02 Volume 1,177,400
Day high $2.26 Avg. volume 1,002,952
50-day MA $2.15 Dividend yield N/A
200-day MA $2.18 Market Cap 566.63M

LYEL Stock Price Chart Interactive Chart >

LYEL POWR Grades

  • Value is the dimension where LYEL ranks best; there it ranks ahead of 67.01% of US stocks.
  • The strongest trend for LYEL is in Growth, which has been heading up over the past 26 weeks.
  • LYEL ranks lowest in Momentum; there it ranks in the 10th percentile.

LYEL Stock Summary

  • LYEL's went public 2.55 years ago, making it older than just 6.63% of listed US stocks we're tracking.
  • With a price/sales ratio of 10.33, LYELL IMMUNOPHARMA INC has a higher such ratio than 89.71% of stocks in our set.
  • LYEL's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of only 10.23% of US stocks.
  • Stocks that are quantitatively similar to LYEL, based on their financial statements, market capitalization, and price volatility, are JANX, KRON, STOK, PLRX, and PRAX.
  • LYEL's SEC filings can be seen here. And to visit LYELL IMMUNOPHARMA INC's official web site, go to www.lyell.com.

LYEL Valuation Summary

  • In comparison to the median Healthcare stock, LYEL's price/earnings ratio is 108.92% lower, now standing at -2.6.
  • Over the past 31 months, LYEL's price/earnings ratio has gone up 17.1.

Below are key valuation metrics over time for LYEL.

Stock Date P/S P/B P/E EV/EBIT
LYEL 2023-12-29 10.1 0.7 -2.6 -1.4
LYEL 2023-12-28 11.0 0.8 -2.8 -1.6
LYEL 2023-12-27 11.0 0.8 -2.8 -1.6
LYEL 2023-12-26 11.1 0.8 -2.8 -1.6
LYEL 2023-12-22 11.0 0.8 -2.8 -1.6
LYEL 2023-12-21 10.4 0.7 -2.6 -1.5

LYEL Price Target

For more insight on analysts targets of LYEL, see our LYEL price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $25.50 Average Broker Recommendation 1.38 (Strong Buy)

Lyell Immunopharma, Inc. (LYEL) Company Bio


Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate population of T cells with durable stemness. Its pipeline includes LYL797, a T cell product candidate for the treatment of non-small cell lung cancer and triple negative breast cancers, as well as ovarian and other solid tumors; LYL845, an IV administered autologous TIL therapy for multiple solid tumors; and NY-ESO-1, a T cell product candidate for synovial sarcoma and other solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California with additional offices in Seattle and Bothell, Washington.


LYEL Latest News Stream


Event/Time News Detail
Loading, please wait...

LYEL Latest Social Stream


Loading social stream, please wait...

View Full LYEL Social Stream

Latest LYEL News From Around the Web

Below are the latest news stories about LYELL IMMUNOPHARMA INC that investors may wish to consider to help them evaluate LYEL as an investment opportunity.

Lyell Immunopharma Receives FDA Orphan Drug Designation for LYL845 for the Treatment of Melanoma

SOUTH SAN FRANCISCO, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation to LYL845, an investigational tumor infiltrating lymphocyte (TIL) product candidate for the treatment of patients with stage IIB-IV melanoma. “There remains a high unmet medi

Yahoo | November 9, 2023

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023

Extended funding of operations into 2027 by prioritizing investment in core clinical candidates and research platform value drivers as well as de-prioritizing selected early-stage research programsRemain on track to release initial clinical data from two clinical-stage product candidates in 2024Entered into proof-of-concept manufacturing collaboration with Cellares for CAR T cell product candidatePresented six abstracts at SITC highlighting innovations designed to shorten TIL manufacturing, new

Yahoo | November 7, 2023

Lyell Immunopharma Presentations at SITC Highlight New Nonclinical Data on Product Candidates and Innovative Technology to Shorten TIL Manufacturing

Six presentations highlight innovations designed to shorten TIL manufacturing, new nonclinical data on LYL119, new technologies and clinical trials in progressSOUTH SAN FRANCISCO, Calif., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, is presenting new nonclinical data at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

Yahoo | October 31, 2023

Lyell Immunopharma, Inc. (NASDAQ:LYEL) has caught the attention of institutional investors who hold a sizeable 49% stake

Key Insights Institutions' substantial holdings in Lyell Immunopharma implies that they have significant influence over...

Yahoo | October 9, 2023

Lyell Immunopharma Announces the Acceptance of Six Abstracts for Presentation at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Presentations to highlight new nonclinical data on product candidates, new technologies, innovations designed to shorten TIL manufacturing and clinical trials in progressSOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell reprogramming company advancing a diverse pipeline of cell therapies for patients with solid tumors, announced today that six abstracts highlighting its broad pipeline of clinical and preclinical produ

Yahoo | September 27, 2023

Read More 'LYEL' Stories Here

LYEL Price Returns

1-mo -21.48%
3-mo 14.95%
6-mo 51.70%
1-year 3.72%
3-year N/A
5-year N/A
YTD 14.95%
2023 -44.09%
2022 -55.17%
2021 N/A
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!